Viveka Roychowdhury

After three consecutive years of negative EBITDA, Panacea Biotec looks set to script a successful revival. Dr Rajesh Jain, Joint…

While we are urged to look beyond the sticky issues, one cannot overlook the final impact of decisions on India's IPR policy

The Health Ministry has predictably stirred a hornet's nest with its diktat to replace PET with glass packaging for certain…

CDSCO's planned 'harmonisation of recruitment rules' is sure to resurrect this debate

As the adage goes, look before you leap

The government is doing many positive things in the biosciences, but could do more, in terms of how it sees research activities,…

Now that India’s competition watch dog, the Competition Commission of India (CCI) has given its nod to Sun Pharma’s acquisition of…

The panel discussed impediments and opportunities facing Indian pharma as it transitioned form a volumes to a value play

The Awards ceremony will be preceded by a panel discussion on 'From Volumes to Value Play: Towards Achieving Vision 2020'

Suresh Pareek, Managing Director, Ideal Cures reveals his strategies and expectations from the CPhI India 2014 show, in an…